These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3567 related items for PubMed ID: 32507409

  • 1. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, Dekker CL, Didierlaurent AM, Graham BS, Martin SD, Molrine DC, Perlman S, Picard-Fraser PA, Pollard AJ, Qin C, Subbarao K, Cramer JP.
    Vaccine; 2020 Jun 26; 38(31):4783-4791. PubMed ID: 32507409
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
    Al-Kassmy J, Pedersen J, Kobinger G.
    Viruses; 2020 Aug 07; 12(8):. PubMed ID: 32784685
    [Abstract] [Full Text] [Related]

  • 4. The 2020 Pandemic: Current SARS-CoV-2 Vaccine Development.
    Alturki SO, Alturki SO, Connors J, Cusimano G, Kutzler MA, Izmirly AM, Haddad EK.
    Front Immunol; 2020 Aug 07; 11():1880. PubMed ID: 32973779
    [Abstract] [Full Text] [Related]

  • 5. A perspective on potential antibody-dependent enhancement of SARS-CoV-2.
    Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, Lanzavecchia A, Corti D, Virgin HW.
    Nature; 2020 Aug 07; 584(7821):353-363. PubMed ID: 32659783
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A systematic review of SARS-CoV-2 vaccine candidates.
    Dong Y, Dai T, Wei Y, Zhang L, Zheng M, Zhou F.
    Signal Transduct Target Ther; 2020 Oct 13; 5(1):237. PubMed ID: 33051445
    [Abstract] [Full Text] [Related]

  • 11. [Strategies for vaccine development of COVID-19].
    Yang L, Tian D, Liu W.
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr 25; 36(4):593-604. PubMed ID: 32347054
    [Abstract] [Full Text] [Related]

  • 12. The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
    Kochhar S, Excler JL, Kim D, Robertson JS, Fast PE, Condit RC, Drew S, Wood D, Gurwith M, Klug B, Whelan M, Khuri-Bulos N, Mallett Moore T, Smith ER, Chen RT, Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG). Electronic address: brightoncollaborationv3swg@gmail.com.
    Vaccine; 2020 Sep 03; 38(39):6184-6189. PubMed ID: 32747214
    [Abstract] [Full Text] [Related]

  • 13. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP, Gupta V.
    Virus Res; 2020 Oct 15; 288():198114. PubMed ID: 32800805
    [Abstract] [Full Text] [Related]

  • 14. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X.
    JAMA; 2020 Sep 08; 324(10):951-960. PubMed ID: 32789505
    [Abstract] [Full Text] [Related]

  • 15. Immunological considerations for COVID-19 vaccine strategies.
    Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z.
    Nat Rev Immunol; 2020 Oct 08; 20(10):615-632. PubMed ID: 32887954
    [Abstract] [Full Text] [Related]

  • 16. COVID-19 shot protects monkeys.
    Cohen J.
    Science; 2020 May 01; 368(6490):456-457. PubMed ID: 32355008
    [No Abstract] [Full Text] [Related]

  • 17. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.
    Gupta T, Gupta SK.
    Int Immunopharmacol; 2020 Sep 01; 86():106717. PubMed ID: 32585611
    [Abstract] [Full Text] [Related]

  • 18. Antibody-dependent enhancement of coronavirus.
    Wen J, Cheng Y, Ling R, Dai Y, Huang B, Huang W, Zhang S, Jiang Y.
    Int J Infect Dis; 2020 Nov 01; 100():483-489. PubMed ID: 32920233
    [Abstract] [Full Text] [Related]

  • 19. Keeping track of the SARS-CoV-2 vaccine pipeline.
    Parker EPK, Shrotri M, Kampmann B.
    Nat Rev Immunol; 2020 Nov 01; 20(11):650. PubMed ID: 32989290
    [Abstract] [Full Text] [Related]

  • 20. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
    De León-Rodríguez SG, Hernández-Rico B, Olmo-Vázquez GD, Cruz-Dávalos I, Bonifaz LC.
    Bol Med Hosp Infant Mex; 2020 Nov 01; 77(5):252-261. PubMed ID: 33064679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 179.